Chordate Medical ("Chordate", "the company") has engaged a market expert in Finland to introduce the company's product K.O.S for preventive migraine treatment on the Finnish market. After the very positive subgroup results and the fact that Finnish clinics are part of the larger study that Chordate is conducting, the company believes that the potential for a good reception from the Finnish market is high.
Chordate has recently completed a clinical study of preventive treatment for chronic migraine, including 97 German patients, who were treated at 5 neurology clinics. According to a published sub-analysis of the German results, K.O.S is indicated to be an effective and safe alternative for the preventive treatment of chronic migraine. And because K.O.S is a non-pharmaceutical option, it would provide a valuable addition to current treatment interventions, without the significant risk of unwanted side effects commonly seen with other preventive treatment options.
The total patient study includes, in addition to Germany, also 40 patients at 4 clinics in Finland, data is still subject to analysis but will be published to the market as soon as possible.
In the work for market access with the migraine indication, Chordate has gradually switched to engaging market experts to build up networks of opinion-leading neurologists, management of reimbursement issues, and early market activities. At the same time, the collaboration with the former distributor for the Nordic region has ended.
“With the fantastic results from the German subgroup analysis, we have received scientific support to broaden the investment in chronic migraine. In Finland, we now use a hired expert in launch and market access for MedTech. Kaija Hämäläinen has extensive experience from the neurology market and a wide network of contacts. In the wake of the German partial analysis, we see a clear potential in Finland that we immediately want to exploit, in the same way that we have already started work on market introduction in Germany, the UK and Israel”, says Anders Weilandt, CEO of Chordate.
